The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents

Physiology and Behavior

Volumn 110-111, Issue , 2013, Pages 42-50

  Westrich, Ligia ^a   Sprouse, Jeffrey ^b   Sánchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

^b Sprouse Consulting   (United States)

Author keywords

Circadian rhythms; PER2::LUCIFERASE; Period; Serotonin receptor; Serotonin transporter; Suprachiasmatic nucleus

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; ESCITALOPRAM; SEROTONIN 7 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

EID: 84872394086     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2012.12.009     Document Type: Article

References (69)

1. Antle M.C., Silver R. Orchestrating time: arrangements of the brain circadian clock. Trends Neurosci 2005, 28:145-151.
2. Moore R.Y. Organization of the primate circadian system. J Biol Rhythms 1993, 8:S3-S9. [Suppl.].
3. Cuninkova L., Brown S.A. Peripheral circadian oscillators: interesting mechanisms and powerful tools. Ann N Y Acad Sci 2008, 1129:358-370.
4. Stratmann M., Schibler U. Properties, entrainment, and physiological functions of mammalian peripheral oscillators. J Biol Rhythms 2006, 21:494-506.
5. Hastings M., O'Neill J.S., Maywood E.S. Circadian clocks: regulators of endocrine and metabolic rhythms. J Endocrinol 2007, 195:187-198.
6. Reppert S.M., Weaver D.R. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001, 63:647-676.
7. Roenneberg T., Chua E.J., Bernardo R., Mendoza E. Modelling biological rhythms. Curr Biol 2008, 18:R826-R835.
8. Mrosovsky N. Locomotor activity and non-photic influences on circadian clocks. Biol Rev Camb Philos Soc 1996, 71:343-372.
9. Weinert D. Ontogenetic development of the mammalian circadian system. Chronobiol Int 2005, 22:179-205.
10. Morin L.P. Serotonin and the regulation of mammalian circadian rhythmicity. Ann Med 1999, 31:12-33.
11. Duncan M.J., Franklin K.M. Expression of 5-HT7 receptor mRNA in the hamster brain: effect of aging and association with calbindin-D28K expression. Brain Res 2007, 1143:70-77.
12. Duncan M.J., Short J., Wheeler D.L. Comparison of the effects of aging on 5-HT7 and 5-HT1A receptors in discrete regions of the circadian timing system in hamsters. Brain Res 1999, 829:39-45.
13. Glass J.D., Grossman G.H., Farnbauch L., DiNardo L. Midbrain raphe modulation of nonphotic circadian clock resetting and 5-HT release in the mammalian suprachiasmatic nucleus. J Neurosci 2003, 23:7451-7460.
14. Pickard G.E., Smith B.N., Belenky M., Rea M.A., Dudek F.E., Sollars P.J. 5-HT1B receptor-mediated presynaptic inhibition of retinal input to the suprachiasmatic nucleus. J Neurosci 1999, 19:4034-4045.
15. Smith B.N., Sollars P.J., Dudek F.E., Pickard G.E. Serotonergic modulation of retinal input to the mouse suprachiasmatic nucleus mediated by 5-HT1B and 5-HT7 receptors. J Biol Rhythms 2001, 16:25-38.
16. Sprouse J., Reynolds L., Li X., Braselton J., Schmidt A. 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology 2004, 46:52-62.
17. Lovenberg T.W., Baron B.M., de Lecea L., Miller J.D., Prosser R.A., Rea M.A., et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993, 11:449-458.
18. Ying S.W., Rusak B. 5-HT7 receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. Brain Res 1997, 755:246-254.
19. Ehlen J.C., Grossman G.H., Glass J.D. In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus. J Neurosci 2001, 21:5351-5357.
20. Leopoldo M., Lacivita E., Berardi F., Perrone R., Hedlund P.B. Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 2011, 129:120-148.
21. Mullins U.L., Gianutsos G., Eison A.S. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999, 21:352-367.
22. Roberts A.J., Krucker T., Levy C.L., Slanina K.A., Sutcliffe J.G., Hedlund P.B. Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur J Neurosci 2004, 19:1913-1922.
23. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994, 268:1403-1410.
24. Thomas D.R., Melotto S., Massagrande M., Gribble A.D., Jeffrey P., Stevens A.J., et al. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 2003, 139:705-714.
25. Nikiforuk A. Selective blockade of 5-HT7 receptors facilitates attentional set-shifting in stressed and control rats. Behav Brain Res 2012, 226:118-123.
26. Huang W., Ramsey K.M., Marcheva B., Bass J. Circadian rhythms, sleep, and metabolism. J Clin Invest 2011, 121:2133-2141.
27. Takeda N., Maemura K. Circadian clock and cardiovascular disease. J Cardiol 2011, 57:249-256.
28. Yu E.A., Weaver D.R. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany NY) 2011, 3:479-493.
29. Kronfeld-Schor N., Einat H. Circadian rhythms and depression: human psychopathology and animal models. Neuropharmacology 2011, 62:101-114.
30. Boivin D.B. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 2000, 25:446-458.
31. Harvey A.G. Sleep and circadian functioning: critical mechanisms in the mood disorders?. Annu Rev Clin Psychol 2011, 7:297-319.
32. Hickie I.B., Rogers N.L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378:621-631.
33. Westrich L., Sprouse J. Circadian rhythm dysregulation in bipolar disorder. Curr Opin Investig Drugs 2010, 11:779-787.
34. Duncan M.J., Hester J.M., Hopper J.A., Franklin K.M. The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. Eur J Neurosci 2010, 31:1646-1654.
35. Gannon R.L., Millan M.J. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology (Berl) 2007, 195:325-332.
36. Gannon R.L., Peglion J.L., Millan M.J. Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: interaction studies with citalopram. Eur Neuropsychopharmacol 2009, 19:887-897.
37. Nomura K., Castanon-Cervantes O., Davidson A., Fukuhara C. Selective serotonin reuptake inhibitors and raft inhibitors shorten the period of Period1-driven circadian bioluminescence rhythms in rat-1 fibroblasts. Life Sci 2008, 82:1169-1174.
38. Possidente B., Lumia A.R., McEldowney S., Rapp M. Fluoxetine shortens circadian period for wheel running activity in mice. Brain Res Bull 1992, 28:629-631.
39. Bonaventure P., Kelly L., Aluisio L., Shelton J., Lord B., Galici R., et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007, 321:690-698.
40. Hedlund P.B., Huitron-Resendiz S., Henriksen S.J., Sutcliffe J.G. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 2005, 58:831-837.
41. Mnie-Filali O., Faure C., Lambas-Senas L., El Mansari M., Belblidia H., Gondard E., et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011, 36:1275-1288.
42. Yamazaki S., Takahashi J.S. Real-time luminescence reporting of circadian gene expression in mammals. Methods Enzymol 2005, 393:288-301.
43. Yoo S.H., Yamazaki S., Lowrey P.L., Shimomura K., Ko C.H., Buhr E.D., et al. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A 2004, 101:5339-5346.
44. Hagan J.J., Price G.W., Jeffrey P., Deeks N.J., Stean T., Piper D., et al. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 2000, 130:539-548.
45. Edgar D.M., Miller J.D., Prosser R.A., Dean R.R., Dement W.C. Serotonin and the mammalian circadian system: II. Phase-shifting rat behavioral rhythms with serotonergic agonists. J Biol Rhythms 1993, 8:17-31.
46. Bosker F.J., Folgering J.H., Gladkevich A.V., Schmidt A., van der Hart M.C., Sprouse J., et al. Antagonism of 5-HT(1A) receptors uncovers an excitatory effect of SSRIs on 5-HT neuronal activity, an action probably mediated by 5-HT(7) receptors. J Neurochem 2009, 108:1126-1135.
47. Vela Hernandez JM, Torrens-Jover A, Buschmann H, Romero-Alonzo L. Use of 5-HT7 receptor agonists for the treatment of pain. International application published under the patent cooperation treaty (PCT) WO 2008/000495 A1 2008.
48. Antle M.C., Ogilvie M.D., Pickard G.E., Mistlberger R.E. Response of the mouse circadian system to serotonin 1A/2/7 agonists in vivo: surprisingly little. J Biol Rhythms 2003, 18:145-158.
49. Klemfuss H., Kripke D.F. Antidepressant and depressogenic drugs lack consistent effects on hamster circadian rhythms. Psychiatry Res 1994, 53:173-184.
50. Sprouse J., Braselton J., Reynolds L. Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biol Psychiatry 2006, 60:896-899.
51. Sprouse J., Reynolds L., Braselton J., Schmidt A. Serotonin-induced phase advances of SCN neuronal firing in vitro: a possible role for 5-HT5A receptors?. Synapse 2004, 54:111-118.
52. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
53. Gannon R.L. 5HT7 receptors in the rodent suprachiasmatic nucleus. J Biol Rhythms 2001, 16:19-24.
54. Westrich L., Bisulco S., Sprouse J. Modulation of GSK-3β kinase phosphorylation state as a determinant of circadian behavior: effects of lithium and 8-OH-DPAT. Program No. 869.7. Neuroscience Meeting Planner 2009, Society for Neuroscience, Chicago, IL, [Online].
55. Prosser R.A., Dean R.R., Edgar D.M., Heller H.C., Miller J.D. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists. J Biol Rhythms 1993, 8:1-16.
56. Sleight A.J., Carolo C., Petit N., Zwingelstein C., Bourson A. Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol Pharmacol 1995, 47:99-103.
57. Graff C., Challet E., Pevet P., Wollnik F. 5-HT3 receptor-mediated photic-like responses of the circadian clock in the rat. Neuropharmacology 2007, 52:662-671.
58. Roca A.L., Weaver D.R., Reppert S.M. Serotonin receptor gene expression in the rat suprachiasmatic nuclei. Brain Res 1993, 608:159-165.
59. Duncan M.J., Congleton M.R. Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. Brain Res 2010, 1366:110-119.
60. Duncan M.J., Grear K.E., Hoskins M.A. Aging and SB-269970-A, a selective 5-HT7 receptor antagonist, attenuate circadian phase advances induced by microinjections of serotonergic drugs in the hamster dorsal raphe nucleus. Brain Res 2004, 1008:40-48.
61. Dallaspezia S., Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother 2011, 11:961-970.
62. Wehr T.A., Wirz-Justice A., Goodwin F.K., Duncan W., Gillin J.C. Phase advance of the circadian sleep-wake cycle as an antidepressant. Science 1979, 206:710-713.
63. Croxtall J.D., Scott L.J. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010, 24:245-262.
64. Deeks E.D., Keating G.M. Spotlight on olanzapine/fluoxetine in acute bipolar depression. CNS Drugs 2008, 22:793-795.
65. Hirose S., Ashby C.R. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002, 63:733-736.
66. Ostroff R.B., Nelson J.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999, 60:256-259.
67. Shelton R.C., Stahl S.M. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004, 65:1715-1719.
68. Rauly-Lestienne I., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A., Cussac D. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol 2007, 376:93-105.
69. Sharpley A.L., Attenburrow M.E., Hafizi S., Cowen P.J. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005, 66:450-454.